The burden-of-illness study on osteoporosis in the Slovenian female population
- 95 Downloads
This burden-of-illness study on osteoporosis was performed with the main goal to estimate the economic implications of osteoporosis for the Slovenian healthcare system.
A variety of sources was used to quantify the utilization of resources in 2003, and the appropriate unit costs were assigned to the identified resources.
Main outcome measures
The study included all direct and indirect costs that arise from treatment of osteoporosis and consequent hip, spine and wrist fractures in total Slovene postmenopausal population in 2003.
We estimated the total burden of postmenopausal osteoporosis in Slovenia for 2003 to be over SIT 7.55 billion (approximately €31.5 million); among that, 45% or SIT 3.39 billion (€14.2 million) belong to drug expenditures for osteoporosis treatment and prevention; 29% or SIT 2.2 billion (€9.2 million) include indirect costs for osteoporosis morbidity and mortality, and 26% or SIT 1.95 billion (€8.1 million) belong to direct costs for treatment, hospitalization, and rehabilitation of osteoporotic fractures. Total costs on osteoporotic fractures were however subject to an approximation due to the expert panel-based estimate of proportion of osteoporosis-caused fractures and the limited data on resource utilization for fracture treatment.
Osteoporosis is a costly disease with a significant burden to society and needs to be viewed as an important problem with a complex long-term impact.
KeywordsBone fractures Burden-of-illness Costs Economics Health policy Osteoporosis Slovenia
Biljana Dzajkovska wishes to thank the Slovenian Scientific Foundation for the given fellowship during the postgraduate studies. No sources of funding were used in the preparation of this paper.
Conflicts of Interest
The authors have no conflicts of interest that are directly relevant to the contents of this manuscript.
- 1.WHO Study Group. Assessment of Fracture Risk and its Application to Screening for Postmenopausal Osteoporosis (1994) World Health Organization Technical Report Series 843:5–6Google Scholar
- 3.Morrison A, Wertheimer AI Types of Pharmacoeconomic Evaluation. In: Morrison A, Wertheimer AI, editors. Pharmacoeconomics. A primer for the pharmaceutical industry. Philadelphia: Temple University; 2002Google Scholar
- 4.National Osteoporosis Foundation Status Report. Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Osteoporosis International 1998; 8(S4):S1–S88Google Scholar
- 10.IVZ. Ambulantno predpisovanje zdravil v Sloveniji po ATC klasifikaciji v letu; 2003. Available via <http://www.ivz.si>Google Scholar
- 11.Inštitut za varovanje zdravja Republike Slovenije: Zdravstveni statistični letopis; 2003Google Scholar
- 13.http://www.zzzs.si Google Scholar
- 14.Ferk J Osteoporotični zlomi kolka, zapestja in hrbteničnega vretenca ter stroški zdravljenja Zdravniški Vestnik 2002;71:41–44Google Scholar
- 16.www.gov.si/zrs/Google Scholar
- 17.http://www.stat.siGoogle Scholar